Financial Snapshot

Revenue
$2.266B
TTM
Gross Margin
Net Earnings
$1.145B
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
153.64%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$10.26B
Q3 2024
Cash
Q3 2024
P/E
13.43
Nov 29, 2024 EST
Free Cash Flow
-$212.4M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $2.355B $2.237B $2.289B $2.122B $1.814B $1.795B $1.598B
YoY Change 5.24% -2.28% 7.87% 16.98% 1.08% 12.33%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $2.355B $2.237B $2.289B $2.122B $1.814B $1.795B $1.598B
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $249.7M $227.3M $182.8M $181.7M $103.4M $61.90M $106.4M
YoY Change 9.87% 24.33% 0.62% 75.73% 67.04% -41.82%
% of Gross Profit
Research & Development $52.00M $177.1M $200.1M $26.30M $83.00M $392.6M $117.9M
YoY Change -70.64% -11.49% 660.84% -68.31% -78.86% 232.99%
% of Gross Profit
Depreciation & Amortization $0.00 $5.670M $23.00M $23.10M $23.90M $33.30M $33.30M
YoY Change -100.0% -75.34% -0.45% -3.35% -28.23% 0.0%
% of Gross Profit
Operating Expenses $52.00M $177.1M $200.1M $26.30M $83.00M $392.6M $658.2M
YoY Change -70.64% -11.49% 660.84% -68.31% -78.86% -40.35%
Operating Profit $1.492B $307.1M $1.431B $1.595B $2.623B $1.364B
YoY Change 385.94% -78.54% -10.32% -39.18% 92.25%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $187.2M $188.0M $166.1M $157.1M $268.6M $280.0M $352.4M
YoY Change -0.41% 13.13% 5.78% -41.52% -4.07% -20.56%
% of Operating Profit 12.54% 61.21% 11.61% 9.84% 10.24% 20.52%
Other Income/Expense, Net $207.9M -$77.00M -$189.5M $106.6M -$161.8M $153.4M -$1.600M
YoY Change -370.05% -59.37% -277.86% -165.87% -205.44% -9688.06%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income $1.700B $230.1M $1.241B $1.702B $2.461B $1.518B $1.343B
YoY Change 638.96% -81.46% -27.07% -30.85% 62.16% 13.0%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Earnings $1.135B $42.83M $619.7M $975.0M $2.349B $1.378B $1.210B
YoY Change 2549.5% -93.09% -36.44% -58.48% 70.46% 13.86%
Net Earnings / Revenue 48.2% 1.91% 27.07% 45.94% 129.45% 76.76% 75.72%
Basic Earnings Per Share $2.54 $0.10 $1.49 $1.32
Diluted Earnings Per Share $2.53 $0.10 $1.49 $1.32 $3.944M $2.314M $2.032M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $1.234B $2.428B $2.803B $2.649B $793.0M $2.386B
YoY Change -49.18% -13.39% 5.82% 234.05% -66.76%
Cash & Equivalents $477.0M $1.711B $1.541B $1.009B $284.0M $1.924B
Short-Term Investments $756.7M $717.0M $1.262B $1.640B $510.0M $462.0M
Other Short-Term Assets $3.798M $90.52M $6.631M $9.000M $0.00 $24.00M
YoY Change -95.8% 1265.1% -26.32% -100.0%
Inventory
Prepaid Expenses
Receivables $14.24M $16.83M $53.29M $33.00M $34.00M $36.00M
Other Receivables $22.40M $19.77M $15.02M $6.000M $5.000M $163.0M
Total Short-Term Assets $1.274B $2.555B $2.878B $2.697B $832.0M $2.609B
YoY Change -50.13% -11.23% 6.72% 224.16% -68.11%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $15.10B $14.23B $14.63B $13.27B $11.48B $8.667B
YoY Change 6.13% -2.73% 10.27% 15.58% 32.43%
Other Assets $6.522M $29.63M $4.145M $29.00M $88.00M $19.00M
YoY Change -77.99% 614.81% -85.71% -67.05% 363.16%
Total Long-Term Assets $15.11B $14.26B $14.64B $13.32B $11.62B $8.761B
YoY Change 5.96% -2.59% 9.87% 14.68% 32.61%
Total Assets $16.38B $16.81B $17.52B $16.02B $12.45B $11.37B
YoY Change
Accounts Payable $15.17M $7.906M $5.620M $11.00M $11.00M $4.000M
YoY Change 91.82% 40.68% -48.91% 0.0% 175.0%
Accrued Expenses $51.68M $54.16M $57.70M $152.0M
YoY Change -4.58% -6.13% -62.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $997.5M $0.00 $282.0M $281.0M
YoY Change -100.0% -100.0% 0.36%
Total Short-Term Liabilities $161.4M $1.167B $171.3M $308.0M $333.0M $580.0M
YoY Change -86.17% 581.33% -44.4% -7.51% -42.59%
Long-Term Debt $6.135B $6.119B $7.096B $5.817B $5.956B $6.238B
YoY Change 0.27% -13.77% 21.99% -2.33% -4.52%
Other Long-Term Liabilities $900.0K $2.500M $0.00 $19.00M $0.00
YoY Change -64.0% -100.0%
Total Long-Term Liabilities $6.136B $6.121B $7.096B $5.817B $5.975B $6.238B
YoY Change 0.24% -13.74% 21.99% -2.64% -4.22%
Total Liabilities $9.855B $11.19B $11.74B $11.20B $6.344B $6.882B
YoY Change -11.89% -4.72% 4.8% 76.58% -7.82%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 447.6M shares 438.0M shares 414.8M shares 375.4M shares
Diluted Shares Outstanding 602.9M shares 438.0M shares 414.8M shares 375.5M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $15.379 Billion

About Royalty Pharma plc

Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Industry: Pharmaceutical Preparations Peers: BRISTOL MYERS SQUIBB CO Catalent, Inc. Elanco Animal Health Inc ELI LILLY & Co JOHNSON & JOHNSON Merck & Co., Inc. Organon & Co. PFIZER INC Viatris Inc Zoetis Inc.